Ethoxzolamide-d5

Ethoxzolamide-d5 (Redupresin-d5) is deuterium labeled Ethoxzolamide. Ethoxzolamide is a carbonic anhydrase inhibitor with Ki of 1 nM.

3054664-97-7

Redupresin-d5; L-643786-d5; PNU-4191-d5

12352005

Bacterial; Carbonic Anhydrase; Isotope-Labeled Compounds

Anti-infection; Metabolic Enzyme/Protease; Others

COVID-19-immunoregulation

Infection; Inflammation/Immunology

O=S(C1=NC2=CC=C(OC([2H])([2H])C([2H])([2H])[2H])C=C2S1)(N)=O

C9H5D5N2O3S2

263.35

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Maren TH, et al. Relations among IOP reduction, ocular disposition and pharmacology of the carbonic anhydrase inhibitor ethoxzolamide. Exp Eye Res. 1992 Jul;55 (1) :73-9.|[3]Benjamin K. Johnson, et al. The Carbonic Anhydrase Inhibitor Ethoxzolamide Inhibits theMycobacterium tuberculosis PhoPR Regulon and Esx-1 Secretion and Attenuates Virulence. Antimicrob Agents Chemother. 2015 Aug; 59 (8) : 4436–4445.|[4]Song Gao, et al. Development and validation of an UPLC-MS/MS method for the quantification of ethoxzolamide in plasma and bioequivalent buffers: Applications to absorption, brain distribution, and pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Apr 1; 0: 54–59.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-B1480S/

Isotope-Labeled Compounds

No Development Reported